Quoin (QNRX) news
Recent news
Quoin Pharmaceuticals: QRX003 is also currently being evaluated in late-stage clinical trials for Netherton syndrome
Quoin Pharmaceuticals Ltd. is currently evaluating QRX003, a topical serine protease inhibitor, in late-stage clinical trials for the treatment of Netherton syndrome, a rare genetic skin disorder. The ongoing phase 2/3 study, CL-QRX003-004, has reported positive interim results, with the drug…
AInvest Wire · 21h agoQuoin Pharmaceuticals - On track to initiate first-ever clinical trial in peeling skin syndrome before year end
AInvest Wire · 21h agoQuoin Pharmaceuticals announces European Medicines Agency (EMA) grants orphan drug designation for QRX003 for the treatment of peeling skin syndrome
Quoin Pharmaceuticals has announced that the European Medicines Agency (EMA) has granted orphan drug designation for QRX003 for the treatment of peeling skin syndrome. This regulatory recognition is intended to support the development of therapies for rare diseases and may provide certain…
AInvest Wire · 21h agoQuoin Pharmaceuticals Ltd: BTIG initiates coverage with buy rating; target price $14
BTIG, a financial services firm, has initiated coverage on Quoin Pharmaceuticals Ltd with a "buy" rating and a target price of $14 per share. The recommendation reflects the firm’s assessment of the company’s current market position and potential for growth. While no detailed analysis or specific…
AInvest Wire · 2d agoQuoin Pharmaceuticals announces acceptance of QRX003 paper in dermatology and therapy
AInvest Wire · Oct 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.